更新于：2024-11-01

Differentiated Thyroid Gland Carcinoma

分化型甲状腺癌

更新于：2024-11-01

基本信息

别名

DTC - differentiated thyroid cancer、Differentiated Thyroid Cancer、Differentiated Thyroid Carcinoma

+ [14]

简介

An adenocarcinoma that arises from the thyroid gland and shows extensive evidence of follicular cell differentiation. According to the nuclear features of the malignant follicular cells, it is classified either as papillary or follicular carcinoma.

关联

人促甲状腺素 (智核生物)

靶点

TSHR

作用机制

TSHR激动剂

在研机构

苏州智核生物医药科技有限公司初创企业 [+1]

原研机构

苏州智核生物医药科技有限公司初创企业

在研适应症

分化型甲状腺癌

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

中国

首次获批日期2024-04-02

Penpulimab

派安普利单抗

靶点

PD-1

作用机制

PD-1抑制剂

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段批准上市

首次获批国家/地区

中国

首次获批日期2021-08-03

Surufatinib

索凡替尼

靶点

CSF-1R x FGFR1 x VEGFR

作用机制

CSF-1R拮抗剂 [+2]

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段批准上市

首次获批国家/地区

中国

首次获批日期2021-06-18

221

项与分化型甲状腺癌相关的临床试验

NCT06647602 / Not yet recruitingN/A

Comparing Effects of Thyroid Hormone Medication Liothyronine and Levothyroxine in Treatment for Thyroid Cancer

This study will be a multicentre prospective cohort study on TH-substitution with liothyronine (L-T3) and levothyroxine (L-T4) in DTC patients after TH-withdrawal. The first cohort is patients treated in the University Medical Centre Groningen (UMCG) with L-T3 according to standard local protocol. The second cohort is patients treated in the Radboud University Medical Centre (Radboud UMC) with L-T4, also according to standard local protocol. We will compare effects of L-T3 or L-T4 on TSH, Thyroglobulin (Tg), quality of life (QoL), weight and cardiovascular parameters.

开始日期2025-02-01

申办/合作机构

University Medical Center Groningen

[+1]

NCT06440850 / Recruiting临床2期IIT

A Pilot Clinical Trial of Vemurafenib and Cobimetinib as a Redifferentiation Strategy in High-Risk, Radioactive Iodine (RAI) Naïve, BRAFV600E Mutated Differentiated Thyroid Carcinoma Patients Undergoing Initial RAI Therapy

This phase II trial tests how well vemurafenib and cobimetinib work in treating patients with high risk differentiated thyroid carcinoma with BRAFV600E mutation, in preparation for radioactive iodine therapy. Vemurafenib and cobimetinib are used in patients whose cancer has a mutated (changed) form of a gene called BRAF. They are in a class of medications called kinase inhibitors. They work by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Giving vemurafenib and cobimetinib may work better to treat patients with high risk differentiated thyroid carcinoma with BRAFV600E mutation, in preparation for radioactive iodine therapy.

开始日期2024-11-30

申办/合作机构

Hope Medical Center

[+1]

NCT06458036 / Not yet recruiting临床2期IIT

Selpercatinib to Enhance RAI Avidity in Children, Adolescents, and Young Adults With Newly Diagnosed Differentiated Thyroid Cancers Harboring RET Fusions

Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy. However, less than a quarter of patients with lung metastases will achieve a complete response to RAI therapy, and this therapy carries the risk of pulmonary fibrosis and an increasingly recognized risk of secondary malignancies.

开始日期2024-11-01

申办/合作机构

The Children's Hospital of Philadelphia

[+2]

100 项与分化型甲状腺癌相关的临床结果

登录后查看更多信息

100 项与分化型甲状腺癌相关的转化医学

登录后查看更多信息

0 项与分化型甲状腺癌相关的专利（医药）

登录后查看更多信息

11,024

项与分化型甲状腺癌相关的文献（医药）

2024-12-01·Oral Oncology

Pralsetinib as neoadjuvant therapy for RET-Altered differentiated thyroid cancer: Two case reports

Letter

作者: Li, Qiu-Li ; Ji, Qing-Hai ; Huang, Nai-Si ; Meng, Yan ; Chen, Jia-Ying ; Wang, Yu

BACKGROUND5-10% of thyroid cancers are at locally advanced stage. Neoadjuvant targeted therapy will likely create surgical opportunities for these patients with unresectable or borderline resectable tumors. Pralsetinib, a RET inhibitor, has been approved for advanced or metastatic RET-altered thyroid cancer. However, there is no evidence on the efficacy of pralsetinib as neoadjuvant therapy in locally advanced RET-altered thyroid cancer.CASE REPORTTwo patients with locally advanced pappilary thyroid carcinoma (PTC) were treated with pralsetinib (400 mg daily) to reduce tumor size and increase the chance of R0 resection. Both PTCs, characterized by RET-fusion, underwent successful R0 resection without major surgical complications after 4-months neoadjuvant pralsetinib.CONCLUSIONThere is a potential for pralsetinib as a neoadjuvant treatment in PTC with RET-fusion.

2024-11-01·International Journal of Surgery Case Reports

Anaplastic transformation of metastatic papillary thyroid carcinoma lesion histologically mimicking a squamous cell carcinoma: A case report

Article

作者: Martiana, Ryna Zahrotul ; Yulian, Erwin Danil ; Aqil, Faisal Mohammad Rifqi ; Ham, Maria Francisca ; Sugiarto ; Wahyono, Yuddi

INTRODUCTIONThe incidence of anaplastic transformation of thyroid cancer from Papillary Thyroid Carcinoma (PTC) is a rare tumor event, which ranges from 1 to 2 % of all cases of thyroid malignancy. Anaplastic transformation is often reported in primary lesions, but is rarely found in metastatic lesions from Differentiated Thyroid Carcinoma (DTC).PRESENTATION OF CASEThis case report reports a unique tumor process where a 70-year-old woman had a metastatic lesion in the Mandible from PTC which transformed into ATC with histological features resembling squamous cell carcinoma-type. Immunohistochemical examination was able to prove that the lesion in the Mandible is a type of undifferentiated Thyroid carcinoma (anaplastic) with a squamous pattern originating from PTC.DISCUSSIONThis type of tumor with histological variant images that resemble other types of tumors is a challenge for diagnosis and appropriate management, so understanding the variants of this type of ATC is important for better management.CONCLUSIONAlthough rare, anaplastic transformation can occur in metastatic sites of PTC. This necessitates the need for early accurate diagnosis through IHC assessment and somatic mutation testing so that appropriate treatment can be delivered.

2024-11-01·American Journal of Surgical Pathology

Emphasizing the Morphology and Collision Tumors

Article

作者: Chen, Paul Chih-Hsueh ; Rivera, Jonathan P. ; Hang, Jen-Fan ; Yeh, Yi-Chen

Multifocal papillary thyroid carcinomas (PTCs) are common and the majority of the tumors harbor mutual BRAF p.V600E mutation. This study aimed to investigate a contemporary series of multifocal PTCs with discordant molecular drivers. Consecutive thyroidectomies diagnosed with multifocal PTCs ≥0.5 cm between 2019 and 2023 were reviewed. Immunohistochemistry (IHC) for BRAF VE1 was performed for all tumors. Cases with discordant BRAF IHC results or morphologic discrepancy were identified, and BRAF IHC-negative tumors were subjected to RAS Q61R IHC and/or targeted RNA next-generation sequencing. A total of 770 patients with a main PTC ≥0.5 cm were identified; 255 (33.1%) had multifocal disease, and 142 (18.4%) had at least another PTC ≥0.5 cm. Among them, 13 cases (9.2%, 13/142) had discordant molecular drivers. Twelve cases had one or more BRAF-positive PTCs accompanied by a BRAF-negative PTC (3 with CCDC6::RET fusion, 1 with NCOA4::RET fusion, 1 with ACBD5::RET fusion, 2 with ETV6::NTRK3 fusion, 1 with TG::FGFR1 fusion, 1 with LMTK2::BRAF fusion, 1 with AGK::BRAF fusion and RAS p.Q61R mutation, 1 with RAS p.Q61R mutation, and 1 without detectable molecular drivers). The last case had tumors with discordant fusion drivers (VIM::NTRK3 and TNS1::BRAF). Most cases showed tumors that were morphologically distinct (92.3%, 12/13) and occurred in the contralateral lobes (76.9%, 10/13). Notably, we identified 4 cases (30.8%) that presented as collision tumors and 6 cases (46.2%) that showed lymph node metastases, including 2 with simultaneous involvement by tumors with discordant molecular drivers, as novel findings. In summary, a subset (9.2%) of multifocal PTCs had discordant molecular drivers and 84.6% of them were a combination of BRAF-positive and kinase gene fusion-associated PTCs, most with distinct morphologies. Almost half of the cases had nodal metastasis and a third of them showed simultaneous involvement by tumors with discordant molecular drivers. The results highlight the clinical importance of identifying such cases, given the potentially different treatments.

114

项与分化型甲状腺癌相关的新闻（医药）

2024-10-30

·Pharma CMC

刚刚，东诚药业抗癌核药获FDA快速通道资格

刚刚，东诚药业发布公告，其下属公司LNC PHARMA PTE.LTD.申报的177Lu-LNC1004注射液获得FDA授予的快速通道资格，用于治疗至少接受过一种及以上酪氨酸激酶抑制剂的转移性碘-131难治性分化型甲状腺癌患者。据东诚药业公告披露，177Lu-LNC1004注射液是一种靶向成纤维细胞活化蛋白（Fibroblast Activation Protein，FAP）的放射性体内治疗药物，通过将放射性核素镥-177靶向运送至FAP阳性表达的实体瘤实现肿瘤的精准治疗。目前在国内和国外尚无同靶点治疗药物上市。该药物在中国、美国和新加坡均已获得临床试验许可，并处在I期临床试验中。

快速通道临床1期

2024-10-30

·医药观澜

刚刚！东诚药业宣布抗癌核药产品获FDA快速通道资格

▎药明康德内容团队报道今日（10月30日），东诚药业宣布下属公司蓝纳成在研产品177Lu-LNC1004注射液获得美国FDA授予的快速通道资格。该产品用于治疗接受过一种及以上酪氨酸激酶抑制剂的转移性碘-131难治性分化型甲状腺癌患者。 177Lu-LNC1004注射液是一种靶向成纤维细胞活化蛋白（Fibroblast Activation Protein，FAP）的放射性体内治疗药物，通过将放射性核素镥-177靶向运送至FAP阳性表达的实体瘤而实现肿瘤的精准治疗。该产品通过修饰的FAP抑制剂（FAP inhibitor, FAPI），能够特异性地与FAP结合，在未来有可能用于多种肿瘤的治疗。FAP作为一种泛肿瘤靶点，高表达于90%以上上皮源性肿瘤相关的成纤维细胞，在正常组织中无表达或低表达。东诚药业新闻稿表示，在临床前研究中，177Lu-LNC1004在多个肿瘤模型中显示出明显的肿瘤高摄取和更长的滞留时间，能够在较低的剂量下达到显著的肿瘤抑制作用。 177Lu-LNC1004注射液已经在2023年分别取得了美国、新加坡和中国的临床批件，并启动1期临床试验。此外，在研究者发起的临床研究（IIT）中，177Lu-LNC1004注射液在特定肿瘤——转移性碘-131难治性分化型甲状腺癌的治疗中表现出优秀的治疗效果，并在确定的剂量下具有良好的患者耐受性和安全性。公开资料显示，蓝纳成创立于2021年，由东诚药业与国际分子影像及纳米医学领域专家陈小元教授联合创立，专注于全球创新的1类诊疗一体化创新肿瘤核药研发平台的打造，致力于为肿瘤患者提供更加精准和有效的治疗方案，并推动核医学在全球的发展。今年4月，该公司宣布完成3亿元B+轮融资。参考资料： [1]重磅 | 177Lu - LNC1004注射液获得美国FDA快速通道资格认定. Retrieved Oct 30, 2024. From https://mp.weixin.qq.com/s/pvwRg0NYDZLTt8Ja8gvR7w 本文由药明康德内容团队根据公开资料整理编辑，欢迎个人转发至朋友圈。转发授权及其他合作需求，请联系wuxi_media@wuxiapptec.com。免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

快速通道临床1期临床2期

2024-10-23

·正大天晴药业集团

聚焦2024亚洲肺癌大会，走进安罗替尼抗血管生成治疗的真实世界

近日，由国际肺癌研究协会（IASLC）主办的2024亚洲肺癌大会（ACLC）在中国香港成功举办。本次大会上，正大天晴公布了自主研发的1类创新药安罗替尼在非小细胞肺癌（NSCLC）领域的重要研究成果，包括1项口头报告及2项壁报展示，其中一项横跨三年半的真实世界研究向世界展示了安罗替尼的临床潜力。口头报告安罗替尼联合卡度尼利单抗和多西他赛二线治疗免疫经治非小细胞肺癌：一项Ib/II期研究 A Phase Ib/II Study of Second-Line Cadonilimab, Anlotinib and Docetaxel in Patients with Checkpoint Inhibitor (CPI)-Experienced Advanced Non-Small Cell Lung Cancer 内容概要：截至2024年5月31日，该研究共纳入46例驱动基因阴性不可切除且不可根治局晚期或转移性、先前接受过PD-1/L1抑制剂和含铂双药化疗治疗且发生疾病进展的NSCLC患者，采用安罗替尼、卡度尼利单抗、多西他赛三药联合治疗。研究数据显示，46例受试者的6个月无进展生存（PFS）率为56.9%；其中，33例受试者接受了至少1次肿瘤评估，疾病控制率（DCR）为94.0%。研究表明，安罗替尼的三药联合治疗方案有望成为晚期免疫耐药NSCLC患者的二线治疗新选择[1]。壁报展示安罗替尼联合曲美替尼治疗非G12C KRAS突变型非小细胞肺癌：一项单中心、开放标签、单臂研究 Trametinib plus Anlotinib in non-G12C KRAS-mutant Non-Small Cell Lung Cancer: a single-center, open-label, single-cohort study 内容概要：本研究旨在评估安罗替尼和曲美替尼联合治疗非G12C KRAS突变NSCLC的有效性和安全性。截至2024年3月26日，共纳入33例患者。综合分析结果显示，受试者客观缓解率（ORR）为66.7%，中位无进展生存时间（PFS）为10.3个月，疾病控制率（DCR）为97%。本研究为非G12C KRAS突变的NSCLC患者提供了一种潜在的联合治疗策略[2]。安罗替尼单药或联合治疗晚期非小细胞肺癌的疗效和安全性的真实世界研究 A Real-World Study of the Efficacy and Safety of Anlotinib Monotherapy or Combination Therapy in Patients with Advanced Non-Small Cell Lung Cancer 内容概要：本项真实世界研究纳入2020年2月至2023年11月期间接受基于安罗替尼方案治疗的NSCLC患者。患者中位年龄为68岁，一线、二线和三线及以上接受安罗替尼治疗的患者比例分别为13%、33%和20%。以安罗替尼为基础的联合治疗包括联合化疗、联合靶向和联合免疫治疗，分别占10%、10%和15%。综合分析结果显示，患者中位无进展生存时间（PFS）为7.5个月，客观缓解率（ORR）为38%，疾病控制率（DCR）为83%[3]。安罗替尼作为全球首个获批非小细胞肺癌三线治疗的抗血管靶向药，目前已递交9个适应症的上市申请。其中6个适应症已获批上市，包括晚期非小细胞肺癌、软组织肉瘤、三线小细胞肺癌、甲状腺髓样癌、分化型甲状腺癌、一线广泛期小细胞肺癌。自2018年上市以来，安罗替尼已在ASCO、ESMO、WCLC等国际大会中稿数百篇，临床研究包括十余个癌种。作为国际肺癌研究领域的重要盛会，ACLC为全球肺癌专家提供了一个交流合作的平台，推动了肺癌治疗的前沿发展。正大天晴将始终致力于创新药物的研发，为全球肺癌患者提供更多、更好的治疗选择，公司也将积极参与国际交流与合作，为全球健康事业做出更大贡献。参考文献： [1] Baohui Han,et al.Trametinib plus Anlotinib in non-G12C KRAS-mutant Non-Small Cell Lung Cancer: a single-center, open-label, single-cohort study.2024 ACLC. [2] Jun Lu,et al.Trametinib plus Anlotinib in non-G12C KRAS-mutant Non-Small Cell Lung Cancer: a single-center, open-label, single-cohort study.2024 ACLC. [3] Jun Zhu,et al.A Real-World Study of the Efficacy and Safety of Anlotinib Monotherapy or Combination Therapy in Patients with Advanced Non-Small Cell Lung Cancer.2024 ACLC. 声明： 1.本新闻稿旨在促进医药信息的沟通和交流，仅供医疗卫生专业人士参阅，非广告用途。 2.本公司不对任何药品和/或适应症作推荐。 3. 本新闻稿中涉及的信息仅供参考，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。若您想了解具体疾病诊疗信息，请遵从医生或其他医疗卫生专业人士的意见或指导。 ● 亚洲肺癌大会 | 谢承润：让香港成为中国医药创新的“超级增值人” ● 世界乳腺癌防治月：分型而治，正大天晴致力提升乳腺癌治疗获益 ● 破冰“低调”的软组织肉瘤，正大天晴安罗替尼新适应症上市申请获受理 ● 正大天晴2款创新药联合治疗子宫内膜癌研究取得重要进展，亮相2024 IGCS

临床结果免疫疗法